Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:18 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 1,898 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Effect of Drug Clear all

Conditions: Healthy Volunteers
Interventions: Venetoclax; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: Breast Cancer, Drug/Agent Toxicity by Tissue/Organ, Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
Interventions: pyridoxine hydrochloride, Placebo, doxorubicin HCL liposome; Dietary Supplement · Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: Female only
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 8
States / cities: Cleveland, Ohio

Conditions: Cognitive Decline
Interventions: Lion's Mane Study Product; Dietary Supplement
Lead sponsor: M2 Ingredients; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Alcohol Use Disorder
Interventions: Lamotrigine, Placebo; Drug
Lead sponsor: Brown University; Other
Eligibility: 16 Years to 24 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Chemo Brain, Chemotherapy-related Cognitive Impairment, Chemo Fog, Breast Cancer, Chemobrain
Interventions: Transdermal nicotine, Placebo Transdermal Patch; Drug · Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 35 Years to 80 Years · Female only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: HIV Infections, Hepatitis C
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 6
States / cities: Los Angeles, California • Stanford, California • Baltimore, Maryland + 1 more

Conditions: Cocaine Use Disorder, Opioid Use Disorder, Stimulant Use Disorder
Interventions: n-acetylcysteine, Hydromorphone, Placebo n-acetylcystine, Placebo hydromorphone; Drug
Lead sponsor: William Stoops; Other
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 2
States / cities: Lexington, Kentucky

Conditions: Obesity
Interventions: CP-945,598; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Healthy Volunteer
Interventions: ABBV-903, Placebo for ABBV-903, Itraconazole; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: Diabetes Mellitus, Type 2
Interventions: Standardized Risk Assessment; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 450 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2013
U.S. locations: 2
States / cities: Durham, North Carolina

Conditions: Drug/Agent Toxicity by Tissue/Organ, Multiple Myeloma and Plasma Cell Neoplasm
Interventions: anti-thymocyte globulin, sirolimus; Biological · Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Abdominal Pain
Interventions: Morphine Sulfate; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 1 Year to 18 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Epilepsy
Interventions: Brivaracetam, levetiracetam, lorazepam, placebo; Drug · Other
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Drug Addiction
Interventions: Cannabidiol, Placebo; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 35 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Nausea and Vomiting, Nausea, Vomiting
Interventions: Fosaprepitant for Injection, Metoclopramide Injection; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Heart Transplantation, Liver Transplantation, Bone Resorption
Interventions: Zoledronic acid, Alendronate, Placebo Zoledronic Acid, Placebo Alendronate; Drug · Other
Lead sponsor: Columbia University; Other
Eligibility: 20 Years to 70 Years
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Schizophrenia, Schizoaffective Disorder, Weight Gain
Interventions: H218O and 2H2O, administered as a mixed cocktail; Dietary Supplement
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 80 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Opioid-use Disorder, HIV-1-infection, Immune Activation, Inflammation, Methadone, Buprenorphine, Naltrexone, Antiretroviral Treatment
Interventions: Methadone, Buprenorphine/naloxone, XR-Naltrexone; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 65 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hypertension
Interventions: Metoprolol succinate, Nebivolol, Non-invasive measurement of Cardiac Output (CO), Endothelial cell collection, Microvascular perfusion assessment using Definity; Drug · Procedure
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Alzheimer Disease
Interventions: BMS-708163, BMS-708163 + Ketoconazole, Ketoconazole, Fluconazole, BMS-708163 + Fluconazole; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy Participants
Interventions: BMS-986322, Rosuvastatin, Metformin, Glucose, Methotrexate, Leucovorin; Drug · Dietary Supplement
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Platelet Function and Reactivity Tests
Interventions: Sotagliflozin (SOTA) followed by 3 drugs in a random order, Aspirin followed by 3 drugs in a random order, Clopidogrel followed by 3 drugs in a random order, Eliquis followed by 3 drugs in a random order; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 79 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Diabetes Mellitus
Interventions: Pioglitazone, Glimepiride; Drug
Lead sponsor: Takeda; Industry
Eligibility: 35 Years to 85 Years
Enrollment: 547 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 65
States / cities: Birmingham, Alabama • Phoenix, Arizona • Huntington Beach, California + 62 more

Conditions: Quality Improvement
Interventions: Audit and Feedback Bundle, Bi-weekly audit and feedback emails; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: San Francisco, California

Search by objective public record fields.

A Study to Assess Food Effect of Venetoclax New Tablet Formulation in Healthy Female Participants

Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer

Study Evaluating the Quality and Effects of Lion's Mane Product on Cognitive Health

Enhancing the Effects of Alcohol Treatment With Lamotrigine

Nicotinic Treatment of Post-Chemotherapy Subjective Cognitive Impairment: A Pilot Study

Effects of Ribavirin on Zidovudine or Stavudine

Behavioral Effects of Drugs (Inpatient): 43 (Opioids, Cocaine, n-Acetylcysteine)

Study Examing The Effect Of Omeprazole On Safety, Tolerability And How The Body Processes An Experimental Drug

A Study to Assess Adverse Events and How Single and Multiple Ascending Doses of ABBV-903 Move Through the Body in Healthy Adults

Effect of Type 2 Diabetes Genetic Risk Information on Health Behaviors and Outcomes

Antithymocyte Globulin and Sirolimus in Treating Patients With Relapsed Multiple Myeloma

The Effect of Pain Medication in Children With Acute Abdominal Pain and Its Implication Over the Surgeon's Decision

Clinical Study in Healthy Volunteers to Investigate the Neurocognitive Effects of a New Antiepileptic Drug: Brivaracetam

Cannabidiol and Emotional Stimuli

Broadening Antiemetics Research by Comparing the Effectiveness of Fosaprepitant and Metoclopramide

Zoledronic Acid Versus Alendronate for Prevention of Bone Loss After Organ Transplantation

Effects of Antipsychotic Medications on Energy Intake and Expenditure

Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1

Effects of Nebivolol on Skeletal Muscle During Exercise in Hypertensive Patients

Drug-Drug Interaction (DDI) w/Ketoconazole or Fluconazole

A Study Investigating Interactions Between BMS-986322 and Rosuvastatin, Metformin and Methotrexate in Healthy Participants

Comparison of Antiplatelet Effects of Sotagliflozin to FDA-approved Antiplatelet Drugs

Efficacy Study of Pioglitazone Compared to Glimepiride on Coronary Atherosclerotic Disease Progression in Subjects With Type 2 Diabetes Mellitus

The Effect of a Novel Audit and Feedback Bundle on Inpatient Performance